Mitoxantrone, as with other drugs in its class,  may cause [[adverse drug reaction|adverse reactions]] of varying severity, including [[nausea]], [[vomiting]], [[hair loss]], heart damage and [[immunosuppression]], possibly with delayed onset. [[Cardiomyopathy]] is a particularly concerning effect as it is irreversible; thus regular monitoring with [[echocardiogram]]s or [[MUGA scan]]s is recommended for patients.

 


 
Because of the risk of cardiomyopathy, mitoxantrone carries a limit on the cumulative lifetime dose (based on body surface area) in MS patients.<ref name="FDA Postmarket Drug Safety">{{cite web|title=Mitoxantrone Hydrochloride (marketed as Novantrone and generics) â€“ Healthcare Professional Sheet text version|url=http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126445.htm|publisher=U.S. Food and Drug Administration|accessdate=19 September 2014|ref=fdapostmarket}}</ref>

 

